Lenacapavir HIV Prevention Breakthrough: High Efficacy in South African Trials Sparks Access Debate

🌍 A Game-Changer Emerges from South African Research Hubs

The world of HIV prevention has witnessed a monumental shift with lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP) administered just twice a year. Developed by Gilead Sciences, this capsid inhibitor disrupts the HIV virus's ability to replicate by targeting its protein shell, offering a discreet and adherence-friendly alternative to daily pills. In South Africa, where HIV prevalence remains among the highest globally—affecting over 7.5 million people—this breakthrough carries profound implications for public health and research ecosystems.

South African universities, particularly the University of the Witwatersrand (Wits), have been central to validating lenacapavir's potential. Their involvement underscores the nation's growing prowess in clinical trials, positioning higher education institutions as key drivers in combating epidemics. Yet, as excitement builds, debates rage over equitable access, pricing, and integration into overburdened health systems.

Decoding Lenacapavir: From Molecule to Injectable Shield

Lenacapavir (LEN), chemically known as GS-6201, binds to the HIV-1 capsid protein, preventing uncoating and blocking multiple stages of viral replication. Unlike nucleoside reverse transcriptase inhibitors in daily orals like tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), LEN's novel mechanism confers broad activity against drug-resistant strains. Administered subcutaneously in the abdomen every 26 weeks, it achieves sustained plasma levels, eliminating daily dosing burdens.

This innovation addresses key barriers in sub-Saharan Africa: stigma around pill possession, forgetfulness, and supply chain inconsistencies. For women, who face disproportionate HIV risk—girls aged 15-24 are three times more likely to acquire HIV than boys—lenacapavir promises empowerment through simplicity.

PURPOSE 1 Trial: Methodology and South African Backbone

The PURPOSE 1 phase 3 trial, a randomized, blinded study, enrolled 5,298 cisgender adolescent girls and young women (AGYW) aged 16-25 from 54 sites across South Africa (85% of participants) and Uganda. Participants, HIV-negative at baseline, were assigned 2:2:1 to subcutaneous lenacapavir every 26 weeks, daily oral tenofovir alafenamide/emtricitabine (F/TAF), daily TDF/FTC, or background standard of care. Primary endpoint: HIV incidence over 52 weeks.

South African sites included urban hotspots like Hillbrow in Johannesburg, managed by Wits Reproductive Health and HIV Institute (Wits RHI), enrolling 212 participants. Other centers likely involved Desmond Tutu Health Foundation at University of Cape Town (UCT) and Stellenbosch University, reflecting collaborative networks honed over decades of HIV research.

Stunning Efficacy: Zero Infections in Key Arm

Interim results in June 2024 prompted early unblinding: zero HIV infections among 2,134 women on lenacapavir (incidence 0 per 100 person-years), versus 1.6% on daily orals. Full data confirmed 100% efficacy against background incidence of 1.69-2.57 per 100 person-years, outperforming orals by 89-96%. This translates to averting an estimated 28 infections in the lenacapavir arm alone.

Professor Thesla Palanee-Philips of Wits RHI hailed it as "the first HIV prevention trial ever to show zero infections," crediting participant commitment and rigorous site management.

Safety and Tolerability: A Clean Profile

Lenacapavir was well-tolerated, with injection-site reactions (mild swelling, pain) in 69%—mostly resolving quickly. No drug-related serious adverse events or discontinuations due to safety. Compared to orals' gastrointestinal issues, LEN's profile supports long-term use. Ongoing PURPOSE 2 (men/gender-diverse) mirrored results: 96% risk reduction.

• Common AEs: Injection-site reactions (63% lenacapavir vs. 9% placebo)
• Serious AEs: Balanced across arms (4-5%)
• HIV seroconversions: None linked to LEN failure

Wits University: Spearheading SA's Research Leadership

Wits RHI, a Wits flagship, exemplifies higher education's role. With 30+ years in HIV trials (e.g., CAPRISA on tenofovir gel), it enrolled 212 in PURPOSE 1, contributing to global data. Dr. Nkosiphile Ndlovu noted, “We are at the forefront of groundbreaking research as Africans.” This builds capacity: training clinicians, nurses, and data managers, many advancing to faculty positions.

Funding from NIH, Bill & Melinda Gates Foundation bolsters infrastructure, positioning Wits as Africa's premier HIV research hub.

SA Higher Ed Ecosystem: Collaborative Powerhouses

Beyond Wits, UCT's IDM and Desmond Tutu Centre, University of KwaZulu-Natal's HIV Pathogenesis Programme, and Stellenbosch's FAMCRU drive trials. These centers train postgrads in epidemiology, virology, and ethics, producing PhDs who lead global consortia. Government-university partnerships via SAMRC enhance trial readiness, vital as PEPFAR funding wavers.

Challenges persist: Brain drain, funding volatility, but successes like lenacapavir affirm investments in research universities.

The Access Paradox: Triumph Tempered by Equity Hurdles

Despite FDA approval (Yeztugo, June 2025), rollout lags. Initial US price: $28,218/year, but Gilead's voluntary licenses to six generics target $40/person/year by 2027 in low/middle-income countries. In SA, registered Oct 2025, yet debates swirl: Vertical delivery vs. primary care integration? Prioritize treatment (86% suppression) or new PrEP?

The Lancet warns of opportunity costs amid Global Fund cuts ($1.4B less), urging dynamic modeling before scale-up.

Unitaid-Wits Rollout: Bridging Research to Reality

Unitaid-funded study (Dec 2025 start) led by Wits RHI tests real-world integration in DoH clinics, mobiles for AGYW/MSM. Targets high-risk groups, trains providers, gauges adherence. Complements national guidelines, with first doses administered amid Eswatini/Zambia pilots. Challenges: Supply chains, stigma, but digital outreach (200k/month) innovates delivery.

SA's bid for local production via Aspen Pharmacare aims self-reliance.

Future Horizons: University-Led Innovations

SA unis eye pharmacogenomics for LEN optimization, resistance monitoring, combo regimens. Training surges: MSc/PhD programs in clinical trials. Amid US aid threats (39 sites at risk), domestic funding vital. Lenacapavir heralds agency: African researchers shaping global health.

Outlook optimistic: If scaled equitably, could slash new infections by 50% in high-burden areas.

Photo by Haberdoedas on Unsplash